Post
by Joanna45 » Sun Mar 09, 2025 12:54 pm
I find this to be interesting so did some research and I and so glad that the companies are beginning to do research on CAD and PAD plaque in the arteries ..looks promising ..
this is what I found on cavadex..
Based on available information, Cavadex, a product marketed by Cholrem Pty Ltd claiming to reduce cholesterol and plaque buildup in arteries, has received mixed reviews with concerns regarding its efficacy and lack of robust clinical trials, and has been cancelled and withdrawn from further supply due to the company's decision to not market it, meaning there are currently no official reviews or complaints about its use in the market; however, some potential concerns raised include a lack of extensive clinical evidence to support its claims and potential side effects associated with its active ingredient, cyclodextrin, which is still under investigation for its long-term effects on the body.
Key points about Cavadex reviews and complaints:
Limited Clinical Data:
The main criticism surrounding Cavadex is that there is a lack of large-scale, peer-reviewed clinical trials to definitively prove its effectiveness in reducing cholesterol and plaque buildup in humans.
Manufacturer Claims:
Cholrem, the company behind Cavadex, claims that the product can significantly lower cholesterol and improve liver function based on limited research and anecdotal evidence.
Cyclodextrin Concerns:
While cyclodextrin, the active ingredient in Cavadex, has potential benefits in cholesterol management, its long-term safety and potential side effects are still under investigation.
Market Status:
Cavadex has been cancelled and withdrawn from further supply by the manufacturer, meaning it is no longer available for purchase.